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Introduction
Obstructive sleep apnea (OSA) is an important cause for a number of medical comorbidities and premature mortality . OSA is characterised by recurrent episodes of pharyngeal obstructions during sleep resulting in a reduction in airflow which can cause derangements in gaseous exchange and disturbed sleep .
As a result OSA is associated with a range of adverse outcomes including daytime sleepiness and cognitive dysfunction . It may result in the development of hypertension , cardiovascular disease and abnormalities in glucose metabolism . Moreover, OSA often has a deleterious impact on quality of life and is associated with symptoms of anxiety and depression .
People with serious mental illness (SMI) (defined as major depressive disorder (MDD), bipolar disorder (BD) and schizophrenia spectrum disorders) have significantly poorer physical health than the general population and are at increased risk of comorbidities . Of particular concern is the high prevalence of obesity diabetes (Stubbs , Vancampfort, De Hert, & Alex, 2015 (in press ); Vancampfort, Mitchell, De Hert, & Stubbs, 2015 (in press) ) and metabolic syndrome .
More recently, research has considered the relationship between SMI and respiratory diseases. For instance, in a population cohort study (Partti et al., 2015) demonstrated that schizophrenia is associated with increased odds of having chronic obstructive pulmonary disease (COPD, OR=4.2) and chronic bronchitis (OR=3.8). Furthermore, reduced lung function can negatively influence participation in daily life among patients with schizophrenia. One of the most prevalent respiratory disorder is OSA. Key risk factors for OSA include obesity, craniofacial abnormalities , allergic rhinitis ) and cardiovascular disease . In addition, lifestyle factors such as smoking and alcohol misuse increase an individual's risk of OSA . These comorbidities and lifestyle factors are particularly prevalent among people with SMI and therefore it is reasonable to assume that this group may be at increased risk of OSA. As such, the identification and management of OSA in people with SMI may be important in preventing or attenuating cardio-metabolic comorbidities associated with SMI . The relationship between OSA and cardiovascular disease, stroke, hypertension and altered glucose metabolism is complex and a p p e a r s t o b e b i d i r e c t i o n a l . Nevertheless, understanding the prevalence of OSA in people with SMI is important.
Previously, a number of narrative systematic reviews have considered the prevalence of OSA in schizophrenia , and SMI more generally . Whilst not focussing on OSA, another review established the critical relationship between sleep disturbances generally and bipolar disorder. Although these reviews have advanced the field, a number of limitations persist. First, none have attempted to conduct a meta-analysis and the prevalence of OSA was limited to considering individual studies as single entities or calculating arithmetic means or medians of the prevalence of OSA. Meta-analyses enable the pooling of data across studies in order to provide a more accurate effect size than when individual studies are considered separately . The recent reviews have also considered differing inclusion criteria when reviewing the literature on OSA. For instance, only considered studies measuring OSA confirmed by polysomnography (PSG) the gold standard recognised by the International Classification of Sleep Disorders 2nd edition (ICSD-2) (Medicine, 2005) criteria. However, considered 'sleep disordered breathing' including studies that report OSA from screening questionnaires.
We aimed to conduct a meta-analysis investigating the prevalence of OSA in SMI and investigate diagnostic subgroup differences among people with MDD, BD and schizophrenia when determined according to standardised OSA measures. Where possible, we anticipated conducting a comparative meta-analysis comparing the risk of OSA in people with SMI versus the general population. Moreover, we sought to investigate differences reported in clinical and population cohort studies and conduct meta-regression analyses on potential moderator variables (if reported in at least 4 studies).
Method
This systematic review was conducted in accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines (Stroup et al., 2000) and reported in accordance with the PRISMA statement ) following a predetermined but unpublished protocol.
Inclusion and exclusion criteria
We included observational (clinical or population cohort) studies (prospective, retrospective or cross-sectional) that: (a) included people with a diagnosis of MDD, BD or schizophrenia spectrum disorders according to a structured clinical assessment and/ or meeting standardised diagnostic criteria (e.g. DSM-IV (Association, 2000) or ICD-10 (organisation, 1993)) (b) assessed for OSA in line with the international classification of sleep disorders, 2nd edition diagnostic and coding manual (Medicine, 2005) . This includes PSG (single or split-night) or OSA with apnea-hypopnea index (AHI, the number of episodes of apnea or hypopnea per hour during sleep) ≥ 5 events/h or the respiratory disturbance index (RDI) equivalent (Medicine, 2005) . We excluded studies that measured OSA with screening instruments alone or studies that identified those with SMI using a screening tool alone. When we encountered studies reporting data from the same sample at different time points, we used the most recent data and/or the largest data set. If necessary, we planned to contact study authors to confirm eligibility and/ or to acquire data, although this was not needed.
Information sources and searches
Two independent reviewers (B.S. and M.F.) searched Academic Search Premier, MEDLINE, Psychology and Behavioral Sciences Collection, PsycINFO, SPORTDiscus, CINAHL Plus and Pubmed from inception until June 2015. We used the key words 'bipolar disorder' or 'bipolar*' or 'affective disorders' or 'schizophrenia' or 'psychosis' or 'depression' or major depression AND 'sleep' or 'sleep apnea' or 'obstructive sleep apnea'. In addition, the reference lists of all eligible articles and recent narrative systematic reviews on OSA and sleep disorders in people with SMI were reviewed . Only articles written in Italian or English were included.
Study Selection
After the removal of duplicates, two independent reviewers screened the titles and abstracts of all potentially eligible articles. Both authors applied the eligibility criteria, and a list of full text articles was developed through consensus. The two reviewers then considered the full texts of these articles and the final list of included articles was reached through consensus.
Data Extraction
Two authors (B.S. and M.F.) independently extracted data and recorded this in a predetermined database. The data collected from each article included: study design, geographical location, details of SMI participants (mean age, percentage of males, diagnosis method, body mass index (BMI), details of medications and chronicity of illness) and details regarding diagnosis. In addition, we sought to extract data on the classification of OSA and number diagnosed with OSA.
Methodological quality appraisal
We used the Newcastle Ottawa Scale (NOS; (Wells, Shea., O'Connell, & Peterson) ) to assess the methodological quality of all included articles. We included studies without a control group due to the paucity of data and such studies were treated as cross sectional case controlled studies for the purposes of methodological assessment. Naturally it was anticipated these studies to have a low methodological quality rating. The NOS assesses the quality of non-randomised trials and its validity and reliability has been established (Wells et al.) and such criterion is particularly essential when critically appraising studies without a control group. The NOS focuses on three main methodological features: 1) the selection of the groups, 2) the comparability of the groups and 3) the ascertainment of the outcome of interest. The maximum score that any study can achieve on the NOS is 9 points. Studies that score 5 or more are normally considered of satisfactory methodological quality. Due to the paucity of literature we included studies with a score less than this (due to the absence of a control group). The methodological assessment was independently completed by two authors and consensus was reached through discussion.
Meta-analysis
We pooled individual study data using the DerSimonian-Laird proportion method which calculates pooled prevalence using inverse-variance weighted random effects meta-analysis with StatsDirect ® and Comprehensive Meta-Analysis ® software (version 3). Due to anticipated heterogeneity, a random effects metaanalysis was employed. If there were 3 or more studies with relevant data, we planned to calculate subgroup analyses of the prevalence of OSA according to SMI diagnostic classification. We also anticipated completing separate subgroup analyses investigating the pooled prevalence of OSA in clinical and population cohort studies and conducted a comparative relative risk (RR) meta-analysis to establish if OSA is more common in people with SMI versus controls. We assessed publication bias with the visual inspection of a funnel plot (Higgins JPT & S) and the Begg and Egger tests. Finally, we conducted several meta-regression analyses (if N≥4) to investigate potential moderators (age, percentage males and BMI) with Comprehensive Meta-Analysis ® (version 3). Despite a lack of consensus on the number of studies required for meta-regression, we chose to only conduct meta regression where data was available from 4 or more studies based on recent recommendations . We anticipated conducting meta regression analyses to investigate the influence of mean age, methodological quality, percentage of males, psychopathology/ depressive symptoms, the percentage taking psychotropic and antipsychotic medication.
Results

Search results and study selection
The initial search identified 2,215 publications. After removal of duplicates, 221 abstracts and titles were screened (Figure 1) . At the full text review stage, 62 articles were considered and 50 articles were excluded with reasons which are listed in figure 1. Thus, 12 articles met the eligibility criteria and were included in the review (Ancoli-Israel et al., 1999; Hattori, 2009; . Details regarding the search results including reasons for exclusion of articles are summarised in figure 1.
Figure 1 here
Study and participant characteristics
Across the 12 unique included studies 570,121 unique participants with SMI were included.
One study included a substantial percentage of the participants included in our meta-analysis (about 99.7% of the whole sample). The mean age across the studies of participants was 38.3 years (SD=7.5) and 45.8% of the included participants were male (range=32-80.4%). The mean BMI across 10 studies with complete data was 25.9 (SD=3.7) (overweight). Across the 12 studies, 9 considered OSA in MDD (n=359,378) Hattori, 2009; . Six studies provided data on 72,043 people with BD (Hattori, 2009; and 4 studies provided data on 138,700 people with schizophrenia spectrum disorders (Ancoli-Israel et al., 1999; . Only two of the included studies were population cohort designs and the remainder included clinical samples. The average NOS was 4.25 (range 4-5). Full details of the included studies according to SMI diagnosis are summarised in table 1. Table 1 here
Meta-analysis of the prevalence of OSA in clinical studies
Prevalence of OSA among people with SMI Data were pooled from 1,535 unique participants with SMI resulting in a pooled prevalence of OSA of 25.7% (95% CI 13.9 to 42.4, Q=156 (df=13) p<0.01) (figure 2). The Begg (-0.9, p=0.59) and Egger tests (-0.45, p=0.79) did not demonstrate any evidence of publication bias in the overall pooled analyses.
Prevalence of OSA among different diagnostic subgroups
Data was pooled from 6 clinical studies from 522 people with MDD to establish a pooled prevalence of OSA of 36.3% (95% CI 19.4 to 57.4, Q=82.83, (df=6) p<0.01). The pooled prevalence of OSA among 681 people with BD was 24.5% (95% CI 10.6 to 47.1, Q=26.55 (df=4) p<0.01). The prevalence of OSA among 329 people with schizophrenia was 15.4% (95% CI 5.3 to 37.1, Q=46 (df=3), p<0.01). The prevalence of OSA in in each diagnostic subgroup is presented in figure 2.
Figure 2 here
Sensitivity analyses
Two studies ) focussing on people with MDD were identified as being potentially biased due to the nature of included participants. Therefore, these were removed in a sensitivity analysis and the pooled prevalence of OSA among 378 people with MDD was recalculated at 25.2% (95% CI 10.2 to 50.2, Q= 58, p<0.01). The overall pooled prevalence of OSA in SMI established the pooled prevalence of OSA was 25.5% (95% CI 16.6 to 37. 6, Q=199, p<0.01, n=1,314) .
Meta regression of pooled prevalence of OSA in SMI
Meta regression analysis using data from 10 studies established that a higher mean age predicted an increased prevalence of OSA in the SMI participants (β=0.063, 95% CI 0.0005 to 0.126, z=1.97, p=0.04, R 2 =0.34). Meta-regression with data from 9 studies established that higher BMI predicted increased prevalence of OSA (β=0.1642, 95% CI 0.004 to 0.3701, z=1.56, p=0.04, R 2 =0.23). No relationship was found with the percentage of males in the studies (p>0.05, N=9) or methodological quality according to the NOS (p>0.05, N=10).
Prevalence of OSA in population cohort studies
Data were pooled from 4 samples utilising two studies including 359,378 people with MDD, 72,043 with BD and 138,700 people with schizophrenia. As reported in Figure 3 , the pooled prevalence of OSA among a total of 568,586 people with SMI was 10.7% (95% CI 2.4 to 37.0, 1368.3 (df=3), p<0.01). The pooled prevalence of OSA in MDD, calculated from pooled data from two unique studies was 19.8% (95% CI 2.5 to 70.0).
Figure 3 here
Discussion
General findings
Results our meta-analysis demonstrates in clinical studies that approximately a quarter of people with SMI meet the criteria for OSA. People with MDD appear to have a higher prevalence of OSA compared to people with BD or schizophrenia. However, after the removal of two potentially biased studies the prevalence of OSA in MDD appears similar to BD. When we considered population cohort data only, the pooled prevalence of OSA was lower at 10.7%, although pooled data from the two MDD cohorts suggest that OSA is higher in this population (19.8%). We found that both increasing age and increased BMI predict an elevated prevalence of OSA among people with SMI.
The increased prevalence of OSA in MDD compared to other diagnostic subgroups is of interest and warrants further investigation. It has been previously suggested that sleep fragmentation associated with hypoxaemia and altered serotonergic neurotransmission, as well as common shared risk factors for both MDD and OSA may account for an increased prevalence of OSA in people with MDD (Schroder & O'Hara 2005) . Among pathways linking OSA and MDD, low serotonin levels seem to play an important role since serotonin has been involved in both the development of depression (Muñoz, Mayoralas, Barbé, Pericás, & Agusti, 2000) and might also influence upper airway dilator motor neurons particularly through the hypoglossal nucleus (Canessa et al., 2011) . In people with MDD, the early identification and treatment of OSA seems to correspond to a better improvement of depressive symptoms (Edwards et al., 2015) . OSA and MDD are risk factors for the development of obesity , cardiovascular disease , and metabolic syndrome (Lett et al., 2004) , while there is also an increased risk in both disorders of excessive alcohol consumption ). In addition, given that in the general population OSA is independently associated with metabolic syndrome , cardiovascular disease and abnormalities in glucose metabolism , the identification and management of OSA may prove also a valuable means to prevent cardiovascular disease in people with MDD.
Obtaining the precise prevalence of OSA in the general population is challenging and many cases within the general population are under-recognised , with previous research suggesting 1-2% and 2-4% of women and men are affected . Others have suggested a higher prevalence in studies conducted in clinical settings with ) establishing a prevalence of 24% and 9% in males and females with an AHI>5. Unfortunately, there were insufficient data to enable a comparative meta-analysis to directly compare the prevalence of OSA in people with SMI versus general population controls. Thus, it remains unclear if people with SMI are at increased risk of OSA compared to people in the general population.
However, the pooled prevalence of OSA in MDD was 36.3% which is higher than previous estimates in the general population . Studies that have previously investigated sleep disordered breathing in MDD defined according to structured clinical assessment have reported greatly increased rates of OSA, with odds ratios of over 5, thus also supporting our results that people with MDD are particularly at increased risk . Moreover, a previous narrative systematic review tabulated the median prevalence of OSA in MDD and reported this as 48.1%. Thus, utilising metaanalysis we were able to establish that the prevalence of OSA in MDD in clinical settings appears to be less than that reported previously . It was also possible to pool data from 358,853 people with MDD and establish the prevalence of OSA in population cohort studies is almost one in 5 (19.8%). Given the likely bias attributed to the studies conducted in clinical settings, the prevalence in population studies may be a truer reflection of the actual prevalence of OSA.
The pooled prevalence of OSA in BD in clinical settings was 24.5% and is comparable to clinical studies in the general population , yet higher than the arithmetic median reported in a previous narrative review (19.8%) . Our pooled analysis of 4 clinical studies in schizophrenia established that 15.4% are affected by OSA, lower than reported in the general population. A previous narrative review suggested people with schizophrenia have a particularly high prevalence of OSA .
Our current findings should however be interpreted with caution given the limitations in the available data. Moreover, only one representative study ) adopted a population cohort study approach which reported 4.5% and 6.9% of people with schizophrenia and BD have OSA respectively. Therefore, it is important that future representative research is conducted to attempt to build on the results of our review and establish the true prevalence of OSA in the diagnostic SMI groups.
The finding that increasing BMI is a significant predictor of increased prevalence of OSA is of interest. Many people with SMI experience increased levels of BMI and in particular central adiposity which is known to increase the risk of OSA in the general population . Reasons for high BMI values in people with SMI could be the high prevalence of sedentary lifestyle and the use of antipsychotic medications that could contribute to obesity in this population. Given this finding, there is further need to develop preventive lifestyle interventions to reduce weight gain in people with mental illness. Future work is needed to investigate the impact of medication on OSA risk in people with SMI. Moreover, other sedative medications commonly prescribed to people with SMI such as benzodiazepines may also increase the risk of OSA . Research in the general population has established that men are at particularly increased risk of OSA . However, we were unable to elucidate any gender effects in our meta-regression analyses.
There are a number of reasons why identifying and managing OSA is clinically important among people with SMI. First, OSA can result in neurocognitive and mood deterioration among people with mental health problems through intermittent hypoxia and disrupted sleep . Clearly, this is an unwanted potential consequence among people who already experience compromised cognition and mood instability . Second, if left untreated there are considerable concerns that OSA may increase the risk of cardiovascular disease, impair glucose regulation and increase the risk of metabolic syndrome. Previous work from our group has extensively documented that people with SMI are at risk of metabolic syndrome (Gardner-Sood P et al., 2015 (in press); and diabetes (Stubbs et al., 2015 (in press ); Vancampfort et al., 2015 (in press) ). Emerging evidence has demonstrated a number of mechanisms which underlie the relationship between OSA and metabolic dysregulation including sympathetic activation, oxidative stress and related inflammation . Given that cardiovascular disease is a major cause of premature mortality in people with SMI , the increased prevalence of OSA is a concern. OSA has been identified as a cause of sudden death in the community and among psychiatric patients .The magnitude of the risk is predicted by the presence and severity of nocturnal hypoxemia , an issue of particular concern in psychiatric patients who refuse continuous positive airway pressure (CPAP) or Bilevel Positive Airway Pressure treatment and/or are treated with benzodiazepines or other CNS-depressant psychotropic drugs . A previous Cochrane review suggests that CPAP may be effective in managing OSA, however there are no rigorous trials investigating this in people with SMI .
Limitations
Although this meta-analysis provides novel findings, there are a number of limitations that must be considered, particularly in light of the data available from the included studies.
First, there was some heterogeneity encountered within the study design and participants.
We attempted to negate this by conducting sub-group analyses and meta-regressions.
Second, the pooled analyses on clinical studies of OSA may not be representative of the wider SMI populations. The meta-analyses results drawn from population cohort studies were sparse but may be a more accurate reflection of the prevalence of OSA. However, these should be interpreted in light of the caveats mentioned above (i.e. clinical setting and overshadowing of co-morbid medical conditions in patients with SMI), indicating the frequencies reported may be underestimates. In this sense, one study , which accounted for the overwhelming majority of participants in or meta-analysis reported a lower prevalence of OSA than the other studies included in our analyses. Third, there was inadequate comparative data of healthy controls to conduct a meta-analysis to understand if people with SMI are at increased risk of OSA. Representative research is required to understand this further. Fourth, there was inadequate data on important moderators such as antipsychotic medication which may influence OSA. Future research is clearly required to better understand these relationships. Finally, our meta regression considered the SMI group as a whole since there was insufficient data to consider each diagnostic group separately. However, this might have resulted in potentially spurious results, which should be clarified in larger representative studies within each diagnostic group. Nevertheless, allowing for these caveats our meta-analysis provides the most systematic quantitative analysis of the prevalence and predictors of the OSA in people with SMI.
Conclusion
Our meta-analysis established that 25.7% of people with SMI have OSA. Higher frequencies were found in MDD (36.3%) compared to BD (24.5%) and schizophrenia (15.4%) although for BD and schizophrenia our findings are unclear due to the small number of the studies included for these conditions. Clearly people with SMI are at risk of OSA and this may negatively impact a range of health outcomes and therefore warrants closer attention in clinical practice. Moreover, future representative research is required to better understand the incidence and prevalence of OSA across all people with SMI with a view to developing effective interventions.
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